

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HealthyWay Inc.
健康之路股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2587)

INSIDE INFORMATION

This announcement is made by HealthyWay Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that, based on the preliminary review on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 and the information currently available to the Board, the Group is expected to record a profit of not less than RMB6 million for the six months ended 30 June 2025 as compared to the loss of approximately RMB57.28 million for the six months ended 30 June 2024 as such loss was primarily attributable to (i) the changes in carrying amount of the redemption liabilities arising from the preferential rights of our convertible redeemable preferred shares which have been terminated upon listing of the Company’s shares and (ii) the listing expenses incurred during the preparation of the Company’s listing. Despite such growth, the Group expects to record a decrease in revenue for the six months ended 30 June 2025 of approximately 15% to 18% as compared to the corresponding period in 2024, and a decrease in gross profit for the six months ended 30 June 2025 of approximately 8% to 12% as compared to the gross profit of approximately RMB183.66 million for the six months ended 30 June 2024.

Based on the information currently available, the Board believes that the expected decrease in revenue and gross profit is mainly attributable to (i) the decrease in revenue from our content services primarily because some of our customers have transitioned to direct marketing as part of their revised marketing strategies, thereby reducing their reliance on our real-world study (“**RWS**”) support services; further, competition in the generic drug sector has intensified,

prompting a shift in resources toward commercialization and as a result, some of our customers have reduced their RWS budgets, (ii) the decrease in revenue from our value-based medical services primarily because certain sales agency agreements for our pharmaceutical wholesale business have expired in 2025 and we are in the process of negotiating for new sales agency agreements, and because of the decrease in revenue generated from healthcare service packages as a result of the Company's proactive adjustment of the service structure and categories, and (iii) the decrease in revenue from our digital marketing services primarily due to economic downturn and as a result, some of our customers chose to reduce their spending on advertising and marketing.

As at the date of this announcement, the Company is still in the process of finalizing the Group's interim results for the six months ended 30 June 2025. The information contained in this announcement is only based on a preliminary assessment with reference to the information currently available, including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025, which are yet to be finalised and have not been reviewed by the independent external auditors of the Company, nor reviewed by the audit committee of the Board, and therefore are subject to amendments and adjustments where necessary. The actual interim results of the Group for the six months ended 30 June 2025 may be different from the information contained in this announcement.

Consequently, such financial information should not be relied upon by shareholders and potential investors as being of the same quality as the information associated with the financial statements that have been subject to an audit or review. Shareholders and potential investors must exercise caution when using such data to evaluate the Group's financial conditions and results of operations. Further details of the Group's financial information for the six months ended 30 June 2025 will be disclosed in the Company's interim results announcement for the six months ended 30 June 2025, which is expected to be published in late August 2025.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

HealthyWay Inc.

Zhang Wanneng

*Chairman of the Board, executive director and
chief executive officer*

Fuzhou, the PRC, 8 August 2025

As at the date of this announcement, the Board comprises Mr. Zhang Wanneng and Mr. Chen Jing as executive directors; Mr. Zhang Xiangming as non-executive director; and Mr. Xu Jing, Dr. Lu Tao and Ms. Deng Xiaolan as independent non-executive directors.